	US 12,377,066 B2
	Treatment of diseases associated with biliary system destruction
Ganna Panasyuk, Paris (FR); and Muriel Girard, Issy les Moulineaux (FR)
Assigned to Assistance Publique-Hopitaux de Paris, Paris (FR); Centre National De La Recherche Scientifique, Paris (FR); Institut National de la Santé et de la Recherche Médicale, Paris (FR); and Université de Paris, Paris (FR)
Appl. No. 17/283,843
Filed by Assistance Publique-Hopitaux de Paris, Paris (FR); Centre National De La Recherche Scientifique, Paris (FR); Institut National de la Santé et de la Recherche Médicale, Paris (FR); and Université de Paris, Paris (FR)
PCT Filed Oct. 11, 2019, PCT No. PCT/EP2019/077668 § 371(c)(1), (2) Date Apr. 8, 2021, PCT Pub. No. WO2020/074737, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. 18306343 (EP), filed on Oct. 11, 2018.
Prior Publication US 2021/0379003 A1, Dec. 9, 2021
Int. Cl. A61K 31/216 (2006.01); A61K 9/00 (2006.01); A61K 31/195 (2006.01); A61P 1/16 (2006.01)

CPC A61K 31/216 (2013.01) [A61K 31/195 (2013.01); A61P 1/16 (2018.01); A61K 9/0053 (2013.01)]

14 Claims

1. A method of treatment comprising administering to a patient after hepatoportoenterostomy, an effective amount of a fibrate compound comprising an agonist of the alpha form of PPAR for treatment of biliary atresia.